Fully Human Bifunctional Intrabodies Achieve Graded Reduction of Intracellular Tau and Rescue Survival of MAPT Mutation iPSC-derived Neurons

• Published in: bioRxiv : the preprint server for biology
• Main Authors: D'Brant, Lianna, Rugenstein, Natasha, Na, Su Kyoung, Miller, Michael J, Czajka, Timothy F, Trudeau, Nicole, Fitz, Emily, Tomaszek, Lindsay, Fisher, Elizabeth S, Mash, Ethan, Joy, Shona, Lotz, Steven, Borden, Susan, Stevens, Katherine, Goderie, Susan K, Wang, Yue, Bertucci, Taylor, Karch, Celeste M, Temple, Sally, Butler, David C
• Format: Journal Article
• Language: English
• Published: United States 01.06.2024
• DOI: 10.1101/2024.05.28.596248

Tau protein aggregation is a hallmark of several neurodegenerative diseases, including Alzheimer's disease, frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP), spurring development of tau-lowering therapeutic strategies. Here, we report fully human bifunctional anti-tau-PEST intrabodies that bind the mid-domain of tau to block aggregation and degrade tau via the proteasome using the ornithine decarboxylase (ODC) PEST degron. They effectively reduced tau protein in human iPSC-derived cortical neurons in 2D cultures and 3D organoids, including those with the disease-associated tau mutations R5L, N279K, R406W, and V337M. Anti-tau-hPEST intrabodies facilitated efficient ubiquitin-independent proteolysis, in contrast to tau-lowering approaches that rely on the cell's ubiquitination system. Importantly, they counteracted the proteasome impairment observed in V337M patient-derived cortical neurons and significantly improved neuronal survival. By serial mutagenesis, we created variants of the PEST degron that achieved graded levels of tau reduction. Moderate reduction was as effective as high reduction against tau V337M-induced neural cell death.